SCHEMBL6085124

SCHEMBL6085124

COC(C)C(=O)Nc1ccc(-c2n[nH]cc2-c2nc3cc(Cl)ccc3o2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP3 P42574 3/20 0.61
SENP7 Q9BQF6 2/20 0.61
POLB P06746 2/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
AGPAT2 O15120 2/20 0.52
CETP P11597 8/20 0.51
MAPT P10636 4/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
KDM4E B2RXH2 2/20 0.50
USP2 O75604 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
ESR1 P03372 1/20 0.50
HPGD P15428 1/20 0.50
TSHR P16473 1/20 0.50
HSD17B10 Q99714 1/20 0.50
CEPT1 Q9Y6K0 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6086046 0.85 CASP3 (0.56) CASP3SENP7POLBNPC1RAB9A
SCHEMBL6085071 0.83 CASP3 (0.52) CASP3SENP7POLBNPC1RAB9A
SCHEMBL6085509 0.81 SMN1; SMN2 (0.63) CASP3SENP7NPC1RAB9AAGPAT2
SCHEMBL6085050 0.81 MAPT (0.60) CASP3SENP7POLBNPC1RAB9A
SCHEMBL6085942 0.81 MAPT (0.61) NPC1RAB9AMAPTSMN1; SMN2KDM4E
SCHEMBL6084109 0.81 PTGS2 (0.64) MAPTSMN1; SMN2KDM4EALDH1A1HPGD
SCHEMBL6084901 0.81 POLB (0.62) CASP3SENP7POLBNPC1RAB9A
SCHEMBL6085528 0.81 CETP (0.55) CASP3SENP7POLBNPC1RAB9A
SCHEMBL6086246 0.80 TP53 (0.56) CASP3SENP7POLBNPC1RAB9A
SCHEMBL6083652 0.80 MAPT (0.68) POLBNPC1RAB9ATDP1CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US claimed
EP-1377589-B1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA SPA (IT) 2005-09-07 EP claimed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US claimed
EP-1377589-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-01-07 EP claimed
WO-2002062804-A1 OXAZOLYL-PYRAZOLE DERIVATIVES AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2002-08-15 WO claimed
US-7105535-B2 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2006-09-12 US disclosed
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180881-A1 Oxazolyl-pyrazole derivatives as kinase inhibitors MAP3K15, MAP3K20, MAP3K3 CASP3 889/4885SENP7 2374/4885POLB 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.